Boehringer Ingelheim program for treatment of schizophrenia

Saniona has entered into a drug discovery and development collaboration with Boehringer Ingelheim. The collaboration focuses on research of new small molecule therapeutics that could be capable of restoring brain network activity in patients with schizophrenia. By combining Saniona’s expertise in ion channels and related technology platforms with Boehringer Ingelheim’s R&D operations, we have the potential to advance new treatment options for schizophrenia. The program is in the late drug discovery phase.